Oncomine Comprehensive Assay- 161 Genes

What is Oncomine Comprehensive Assay 161 gene panel test?

A pan‑cancer NGS panel covering 161 clinically relevant genes to report actionable mutations, CNVs, and fusions in one single test. This panel is designed for comprehensive genomic profiling of solid tumors, integrating results into a single interpretive report that maps alterations to potential therapies and trials.

Why consider Oncomine Comprehensive Assay 161 gene panel test?

This panel is recommended for -

• Identifies targetable alterations in 161 genes, thereby enabling targeted therapy decisions.
• Consolidates multiple single‑gene/focused tests into one assay, conserving tissue and shortening time to a comprehensive result that supports multidisciplinary decision‑

Who should get this Oncomine Comprehensive Assay 161 gene panel test?

• Patients with advanced or metastatic solid tumors where broad genomic profiling may uncover actionable targets or clinical trial options, particularly when first‑line targeted options are considered or upon progression.

• Tumors with known genomic heterogeneity or multiple potential drivers (e.g., lung adenocarcinoma, cholangiocarcinoma, ovarian, breast, colorectal, prostate, sarcomas, thyroid, and others) where a single comprehensive assay may outperform sequential testing.
• Cases with limited tissue in which maximizing information from a single assay is critical, or where immunotherapy and PARP inhibitor biomarkers (TMB/MSI/HRD) are clinically relevant.

More Information about Oncomine Comprehensive Assay 161 gene panel test

A comprehensive next‑generation sequencing (NGS) tumor profiling assay that analyzes a broad set of cancer genes to detect multiple variant types—single‑nucleotide variants, insertions/deletions, copy‑number changes, and gene fusions. It is typically performed on FFPE tumor tissue (with matched DNA and RNA inputs when available) to inform targeted therapy selection, clinical trial eligibility, and prognostication across solid tumors.

Other Names: Oncomine comprehensive panel, comprehensive genomic profiling, 161 gene panel, cancer gene panel, CGP panel, cancer multigene panel